Xcout IntelNeOnc Technologies Holdings, Inc. competitors & alternatives
The 12 closest competitors and alternatives to NeOnc Technologies Holdings, Inc. among biotechnology companies — ranked by similarity to what NeOnc Technologies Holdings, Inc. actually does, not by market-cap band.
Subscribe to see NeOnc Technologies Holdings, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About NeOnc Technologies Holdings, Inc.
Neonc Technologies Holdings, Inc. specializes in pioneering molecular advancements aimed at improving the targeted administration of therapies for central nervous system disorders. The company's leading pipeline candidate, NEO100, is presently undergoing Phase 2a clinical trials for the treatment of glioblastoma. Additionally, NEO212, a unique molecular construct chemically linking the chemotherapeutic agent temozolomide with perillyl alcohol, has successfully concluded its preclinical evaluation. This enterprise, founded in 2023, operates from its base in Los Angeles, California.
NeOnc Technologies Holdings, Inc. at a glance
NeOnc Technologies Holdings, Inc. is a biotechnology company headquartered in Calabasas, United States. It is publicly listed (NTHI) with a market capitalisation of $78.1M. Xcout tracks 36 named people at NeOnc Technologies Holdings, Inc., including Amir Farrokh Heshmatpour (President, Chief Executive Officer, Executive Chairman & Secretary).
NeOnc Technologies Holdings, Inc. leadership
- Amir Farrokh HeshmatpourPresident, Chief Executive Officer, Executive Chairman & Secretary
- AMIR HESHMATPOURCEO
- Thomas C. ChenCEO
- Keithly A. GarnettChief Financial Officer
- Josh Neman-EbrahimChief Clinical Officer
- David ChoiChief Accounting Officer
30 more named people on record for NeOnc Technologies Holdings, Inc., with roles, board committees and tenure — see the full roster →
NeOnc Technologies Holdings, Inc. funding rounds before its IPO
The most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $10M | — |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 NeOnc Technologies Holdings, Inc. competitors
Ranked by semantic similarity — how close each company is to NeOnc Technologies Holdings, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Neotx Holdings Ltd. is a biopharmaceutical company that develops cancer therapeutics and immunotherapies. It conducts clinical trials and researches proprietary technologies aimed at advancing cancer treatment.
Similar biotechnology company
Dome Therapeutics is a preclinical biotechnology company developing a nanomedicine designed to target brain cancer stem cells that survive standard glioblastoma treatments and drive tumor recurrence. Using a proprietary nanoparticle delivery platform, the company aims to cross the blood-brain barrier to deliver therapeutic payloads directly to these treatment-resistant cells.
Biotech
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Similar biotechnology company
Gibson Oncology is a biopharmaceutical company that develops treatments for brain cancer, focusing on its lead program involving the drug LMP744 for recurrent glioblastoma. The company is advancing LMP744 through clinical trials, including an NIH-conducted phase II trial for patients who have failed initial therapy.
Biotech
TME Pharma is a clinical-stage biotechnology company that develops novel therapies targeting the tumor microenvironment to treat aggressive cancers such as glioblastoma and pancreatic cancer. Its proprietary technology neutralizes chemokines to break down tumor protection barriers, allowing combination treatments to achieve a greater therapeutic impact.
Similar biotechnology company
BrainChild Bio is a clinical-stage biotechnology company that develops CAR-T cell therapies to treat tumors in the central nervous system (CNS). The company prioritizes pediatric patients with brain tumors while also extending its technology platform to address adult indications such as glioblastoma and brain metastases.
Similar biotechnology company
NCC-Bio is a South Korean biopharmaceutical company founded in 2020 and headquartered in Goyang, focused on developing targeted anti-cancer strategies and therapeutics.
Biotech
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Biotech
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
Biotech
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Biotech
Beyond Bio is a biotechnology company that researches and develops novel therapeutics for various oncological and neurological conditions, including pancreatic cancer, colorectal cancer, glioblastoma, blood cancer, lung cancer, and Alzheimer's disease. The company also develops proprietary drug delivery technologies to support its therapeutic pipeline.
Similar biotechnology company
Neurona Therapeutics Inc. is a biotherapeutics company that focuses on developing cell-based therapies to address neurological disorders.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of NeOnc Technologies Holdings, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for NeOnc Technologies Holdings, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →